Cervical cancer tumor antigens (CCTA)

Cervical cancer tumor antigens represent a group of proteins overexpressed or specifically expressed by cervical cancer cells, serving as primary targets for immunotherapy and diagnostic screening. The most prominent among these are the Human Papillomavirus (HPV) E6 and E7 oncoproteins, which are constitutively expressed in HPV-positive malignant cells and are essential for maintaining the transformed phenotype by degrading tumor suppressors p53 and pRb, respectively (Source: National Cancer Institute, PubMed). Other relevant antigens include p16INK4a, a surrogate marker for HPV-induced transformation, and various cancer-testis antigens like MAGE or NY-ESO-1 that may be aberrantly expressed. Therapeutic strategies targeting these antigens include DNA vaccines, peptide vaccines, and T-cell receptor (TCR) engineered therapies designed to elicit a robust cytotoxic T-lymphocyte response against the tumor (Source: Journal of Clinical Oncology). While highly specific, the collective nature of this term makes it a broad category rather than a single molecular entity, often requiring the identification of specific viral or cellular proteins for precise drug development.

Other names

Cervical cancer-associated antigensHPV-associated tumor antigensHuman papillomavirus E6 and E7 oncoproteinsCervical carcinoma antigens

Therapeutic vaccines induce T-cell mediated immune responses against specific viral oncoproteins (E6/E7); Immune checkpoint inhibitors enhance the existing anti-tumor immune response against these antigens.